an phone calls bring down drug prices? Do mom-and-pop investors have a prayer against hedge funds? And how do you know whether an Alzheimer’s drug actually works?
We discuss all that and more in the latest episode of “The Readout LOUD,” STAT’s biotech podcast. Tune in for a conversation about that mysterious phone call with President Trump that led Pfizer’s CEO to, at least briefly, lower some drug prices. Then we’ll talk to some biotech investors: one about the health skepticism surrounding Biogen’s latest Alzheimer’s study, and another about how retail stock-pickers can get a leg up on biotech’s investing incumbents.
For more on what we cover, here’s the news on Pfizer; here’s the latest on Biogen’s Alzheimer’s program; and here’s a look at how early-stage biotech companies are getting creative when it comes to graphic design.
We’ll be back next Thursday evening — and every Thursday evening — so be sure to sign up on iTunes, Stitcher, Google Play, or wherever you get your podcasts.
And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email email@example.com.
Interested in sponsoring a future episode of “The Readout LOUD”? Email us at firstname.lastname@example.org.